Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887832 | 0.84 | FKBP5 (0.40) | NOS1LRRK2 | |
| SCHEMBL8826272 | 0.83 | CDK1 (0.33) | CDK2PDPK1CCNE1GDAMAP3K5 | |
| SCHEMBL8826188 | 0.81 | NOS1 (0.40) | NOS1CDK2PDPK1CCNE1GDA | |
| SCHEMBL8826203 | 0.81 | CDK1 (0.35) | NOS1CDK2MAP3K5NUDT1CDK1 | |
| SCHEMBL9170908 | 0.81 | JAK1 (0.40) | CDK2CCNE1LRRK2 | |
| SCHEMBL23760858 | 0.80 | PDPK1 (0.37) | CDK2PDPK1CHEK1AURKACHEK2 | |
| SCHEMBL18961871 | 0.80 | ALDH1A1 (0.37) | CDK2PDPK1CHEK1AURKACHEK2 | |
| SCHEMBL6747378 | 0.79 | XDH (0.37) | CDK2PDPK1CHEK1AURKACHEK2 | |
| SCHEMBL20793714 | 0.79 | PDPK1 (0.36) | CDK2PDPK1CHEK1AURKACHEK2 | |
| SCHEMBL30390058 | 0.79 | PDPK1 (0.36) | CDK2PDPK1CHEK1AURKACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4592399-B1 | COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES | DNAE DIAGNOSTICS LTD (GB) | 2026-03-11 | — | — | EP | claimed |
| EP-4592399-A2 | COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES | DNAe Diagnostics Limited (GB) | 2025-07-30 | — | — | EP | claimed |
| EP-4090768-B1 | COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES | DNAE DIAGNOSTICS LTD (GB) | 2024-03-13 | — | — | EP | claimed |
| US-10851407-B2 | Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor | CARNEGIE MELLON UNIVERSITY (US) | 2020-12-01 | — | — | US | claimed |
| EP-2873731-B1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | DNAFORM KK (JP) | 2018-08-29 | — | — | EP | claimed |
| US-20170058325-A1 | Left-Handed Gamma-Peptide Nucleic Acids, Methods of Synthesis and Uses Therefor | CARNEGIE MELLON UNIVERSITY | 2017-03-02 | — | — | US | claimed |
| WO-2015172058-A1 | LEFT-HANDED GAMMA-PEPTIDE NUCLEIC ACIDS, METHODS OF SYNTHESIS AND USES THEREFOR | CARNEGIE MELLON UNIVERSITY (US) | 2015-11-12 | — | — | WO | claimed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | claimed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | claimed |
| JP-2004514440-A | — | — | 2004-05-20 | — | — | JP | claimed |
| EP-1348035-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | Riken (JP) | 2003-10-01 | — | — | EP | claimed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | claimed |
| US-12606864-B2 | Compositions, kits and methods for isolating target polynucleotides | DNAE DIAGNOSTICS LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4704906-A2 | APTAMER-BASED SUSTAINED RELEASE OF THERAPEUTIC AGENTS | The Children's Medical Center Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4592399-B1 | COMPOSITIONS, KITS AND METHODS FOR ISOLATING TARGET POLYNUCLEOTIDES | DNAE DIAGNOSTICS LTD (GB) | 2026-03-11 | — | — | EP | disclosed |
| US-20250269368-A1 | METHOD AND SYSTEM COMPRISING A CARTRIDGE FOR SEQUENCING TARGET POLYNUCLEOTIDES | DNAE GROUP HOLDINGS LTD (GB) | 2025-08-28 | — | — | US | disclosed |
| WO-1993014103-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| CN-1051180-A | The nucleosides that is used for the treatment of | WELLCOME FOUND (GB) | 1991-05-08 | — | — | CN | disclosed |
| EP-0421739-A1 | 3'-azido purine nucleoside | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851407-B2 | Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor | NPPA, POLL, POLI | NOS1 1083/4885CDK2 4373/4885PDPK1 3162/4885 |
| US-12606864-B2 | Compositions, kits and methods for isolating target polynucleotides | CFB, RNGTT, TPM4 | NOS1 4686/4885CDK2 2124/4885PDPK1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.